Evaluation of the risks of developing secondary cancers in patients with chronic myeloproliferative neoplasms from 1957 to 2022.

Evaluation of the risks of developing

secondary cancers in patients with

chronic myeloproliferative neoplasms:

66 Years of Continuous Investigation

From 1957 to 2022.

Daniella Kingsley-Godwin, Maria Jana Kingsley-Godwin, Joshua Kingsley-Godwin and Martin Morgan

London Medical Academy Research Consortium, London, England, United Kingdom

Abstract

The aim of this study is to evaluate of the risks of developing secondary cancers in patients with chronic myeloproliferative neoplasms. Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of developing secondary cancers, such as solid tumors in the skin, lung, kidney, and thyroid, and lymphoid cancers. This risk is linked to both the intrinsic nature of the MPN disease and certain treatments like hydroxyurea, which can increase the risk of non-melanoma skin cancer. Other factors such as age and the presence of specific genetic mutations also influence this risk. 

====================================